NEXAVAR DESIGNATED ORPHAN DRUG

Bayer Pharmaceuticals and Onyx Pharmaceuticals announced the FDA has granted orphan drug status for their cancer drug Nexavar (sorafenib).

Nexavar is used to treat patients with renal cell carcinoma (RCC) or kidney cancer. It has already received a similar designation in the European Union.